DUAL Medicine s.r.o.
- Address
- Hlavne Namestie 24/4, 979 01 Rimavská Sobota, Slovakia
DUAL Medicine s.r.o. - Cardiovascular and Metabolic Research
DUAL Medicine s.r.o. is a clinical research facility specializing in advanced cardiovascular therapeutics and metabolic disorders. The center demonstrates particular expertise in conducting Phase III trials for complex cardiovascular conditions, with a focus on innovative combination therapies and novel pharmacological approaches to managing resistant cardiovascular diseases.
- Heart failure with comorbid kidney dysfunction and cardiovascular mortality prevention
- Uncontrolled and resistant hypertension management
- Novel aldosterone synthase inhibition and SGLT2 inhibitor combination therapies
The research center is actively involved in evaluating next-generation treatments for patients with chronic heart failure and impaired kidney function, investigating the efficacy of balcinrenone/dapagliflozin combinations in reducing heart failure events. Additionally, DUAL Medicine participates in groundbreaking studies of baxdrostat for treatment-resistant hypertension, addressing critical unmet needs in patients whose blood pressure remains uncontrolled despite standard multi-drug regimens including diuretics.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AstraZeneca AB1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in DUAL Medicine s.r.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Baxdrostat in Patients with Uncontrolled and Resistant Hypertension on Multidrug Regimens: A Randomized, Double-Blind, Placebo-Controlled Study | AstraZeneca AB | Phase III | Not Recruiting | Mar 2024 | Oct 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Balcinrenone | 1 | Unknown | 2024-07-12 | 2024-07-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.